Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

Overview
Date Founded

2007

Headquarters

3535 General Atomics Court, Suite 200, San Diego, CA, 92121, USA

Type of Company

Public

Employees (Worldwide)

178

Industries

Biotechnology
Hospitals & Patient Services
Pharmaceuticals

Company Description

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Contact Data
Trying to get in touch with decision makers at Fate Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

General Counsel & Secretary

Chief Development Officer

Chief Scientific Officer

Senior Vice President-Corporate Development

Senior Vice President-Technical Operations

Senior Vice President-Clinical Translation

Senior Vice President-Clinical Development

Co-Founder

Board of Directors

Former Executive Chairman at Biogen, Inc.

Founder at Fate Therapeutics, Inc.

Partner at Polaris Partners

Former Vice President-Financial Services at California Healthcare Institute

Founder at Fate Therapeutics, Inc.

Chief Medical Officer at Epizyme, Inc.

Founding Member at Redmile Group LLC

Executive Vice President of Research & Chief Scientific Officer at Gritstone Oncology, Inc.

Paths to Fate Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Fate Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time.While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Details Hidden

Casdin Capital seeks to realize superior long-term adjusted total returns by primarily investing in underappreciated companies with innovative business models in the life sciences and healthcare industry. Their portfolio is generally comprised of small to mid-sized issuers in the following life sciences and healthcare sub-sectors: life sciences instrumentation and information technology, medical testing, drug development and distribution, synthetic biology and agriculture, livestock management and energy production. In addition, the firm also has discretion to invest in certain foreign equity securities if they determine that investments in such securities could generate risk-adjusted returns for their clients. Casdin Capital employs a primary research-intensive approach to investing that is thematically driven and fundamentally based and uses a range of investment strategies, primarily investing in publicly-traded equity or equivalent securities, both long and short, as well as a broad array of other securities.

Details Hidden

FCM seeks to achieve superior risk-adjusted rates of return through a process of fundamental analysis that emphasizes capital preservation. The firm uses the following sources: a variety of publicly available information sources, including but not limited to financial periodicals, corporate rating services, annual reports, prospectuses and filings with the SEC and other regulators, company press releases, as well as, and to the extent applicable or appropriate, information provided by management and creditors of portfolio companies, brokers, dealers, analysts, professional asset managers, research services and hired consultants and advisers. Historically, FCM's core strategies have included merger arbitrage, credit investments, real estate investments, direct investments and long/short equity. They make investments in public and private debt and equity securities, as well as direct investments in private companies and real estate.

Recent Transactions
Details Hidden

Fate Therapeutics, Inc. issued USD Common Stock

Details Hidden

Fate Therapeutics, Inc. issued . USD Common Stock

Details Hidden

Fate Therapeutics, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onFate Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onFate Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onFate Therapeutics, Inc. issued . USD Common Stock

Legal Advisor

Advised onFate Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onFate Therapeutics, Inc. issued . USD Common Stock

Associate

Advised onFate Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Chairman, Silicon Valley at Goodwin Procter LLP

Legal Advisor

National Co-Chair, Life Sciences Practice at Goodwin Procter LLP

Advisor

Head, Antibody-Dependent Cellular Cytotoxicity Program at University of Minnesota

Clients

Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans E. Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, and Robert T. Nelsen on August 5, 2013 and is headquartered in Seattle, WA.

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.

Key Stats and Financials As of 2019
Market Capitalization
$1.31B
Total Enterprise Value
$1.14B
Earnings Per Share
$-1.44
Revenue
$10.7M
Net Profit
$-98.2M
EBITDA
$-98.5M
EBITDAMargin
-922.6%
Total Debt
$26.9M
Total Equity
$245M
Enterprise Value Sales
106.74x
TEVNet Income
-11.62x
Debt TEV
0.02x
Three Year Compounded Annual Growth Rate Of Revenue
34.37%
Investors
Details Hidden

Polaris Partners invests primarily in companies in the consumer technology, digital media/entertainment, e-Commerce, network hardware, software and semiconductors sectors. They invest in seed, early-stage and high growth, middle-market companies.The firm's early-stage investments focus on information technology and life sciences companies. Within the information technology sector, Polaris looks for companies that are developing Internet and broadband infrastructure, enterprise software products, e-Commerce products/services, digital media/entertainment, consumer software, network hardware and network software.In the life sciences sector, the firm looks for companies that are developing medical devices, pharmaceuticals, genomics, proteomics, drug delivery, medical services and consumer products and services.Polaris' private equity efforts focus on high-growth, middle-market companies in industries including technology, healthcare, digital media, consumer products and services and business services.Polaris serves as the lead or co-lead investor in the vast majority of their portfolio companies. The firm participates in minority growth equity investments, recapitalizations with liquidity and LBOs.

Details Hidden

The California Institute for Regenerative Medicine ("The Institute" or "CIRM") was established in early 2005 following the passage of Proposition 71, the California Stem Cell Research and Cures Initiative. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was approved by California voters on November 2, 2004, and called for the establishment of a new state agency to make grants and provide loans for stem cell research, research facilities and other vital research opportunities. The mission of CIRM is to support and advance stem cell research and regenerative medicine under the highest ethical and medical standards for the discovery and development of cures, therapies, diagnostics and research technologies to relieve human suffering from chronic disease and injury.

Details Hidden

OVP is an active manager which provides equity financing for seed and early-stage capital requirements. The firm targets companies operating in the technology services and healthcare technology sector, and industries such as information technology services, biotechnology and alternative power generation. OVP initially invests between USD 1 and 5 million in companies located in the United States. The firm looks to take minority positions in its investments.

Suppliers
Indiana University Bloomington, INDIANA

Indiana University is a major multi-campus public research institution, grounded in the liberal arts and sciences, and a world leader in professional, medical, and technological education. Indiana University’s mission is to provide broad access to undergraduate, graduate, and continuing education for students throughout Indiana, the United States, and the world, as well as outstanding academic and cultural programs and student services. Indiana University seeks to create dynamic partnerships with the state and local communities in economic, social, and cultural development and to offer leadership in creative solutions for 21st century problems. Indiana University strives to achieve full diversity, and to maintain friendly, collegial, and humane environments, with a strong commitment to academic freedom.

The Children's Medical Center Corp. Hospitals & Patient Services | Boston, MA

The Children's Medical Center Corp. operates as a non-profit hospital and research center. The company was founded in 1959 and is headquartered in Boston, MA.

The Scripps Research Institute Biotechnology | La Jolla, CA

The Scripps Research Institute (TSRI), one of the world's largest, private, non-profit research organizations, stands at the forefront of basic biomedical science, a vital segment of medical research that seeks to comprehend the most fundamental processes of life. Over the last decades, the institute has established a lengthy track record of major contributions to the betterment of health and the human condition. The institute — which is located on campuses in La Jolla, California, and Jupiter, Florida — has become internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases, virology, and synthetic vaccine development. Particularly significant is the institute's study of the basic structure and design of biological molecules; in this arena TSRI is among a handful of the world's leading centers. The institute’s educational programs are also top-rate. The Kellogg School of Science and Technology is currently ranked among the best in the nation in its fields of biology and chemistry. Rather than isolating faculty members, students, and laboratories into separate and distinct disciplines, as is generally prescribed in universities, a cooperative, collaborative spirit is encouraged and embraced. While the level of scientific investigation is intense, the atmosphere is collegial, relaxed, and informal. Technicians, postdoctoral fellows, graduate students, and administrative support staff all are considered part of the team and are given the latitude and responsibility to accomplish their tasks so as to serve the best interests of science. The pursuit of scientific excellence is paramount and all efforts are directed toward that end. The bulk of the institute's funding is derived from the National Institutes of Health and other federal agencies. In today's environment of increasing competition for shrinking federal dollars, however, collaborative industrial partnerships with leading pharmaceutical companies provide additional funding in several areas key to the organization's research objectives. The Scripps Research Institute's adherence to the highest scientific standards, emphasis on a multidisciplinary approach to problem solving, participation in the perpetuation of knowledge through education, and continual pursuit of research excellence provide an unparalleled scientific environment.

Competitors
CRISPR Therapeutics AG Biotechnology - Zug, Che

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

AbbVie, Inc. Pharmaceuticals - North Chicago, IL

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

Novartis AG Pharmaceuticals - Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Fate Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Fate Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Fate Therapeutics, Inc..